The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Karetnikova V.N.
Research Institute for Complex Issues of Cardiovascular Diseases, 6 Sosnovyi Boulvar, 650002, Kemerovo, Russian Federation;
Kemerovo State Medical University, 22a Voroshilova St, 650056, Kemerovo, Russian Federation
Kashtalap V.V.
Research Institute for Complex Issues of Cardiovascular Diseases, 6 Sosnovyi Boulvar, 650002, Kemerovo, Russian Federation;
Kemerovo State Medical University, 22a Voroshilova St, 650056, Kemerovo, Russian Federation
Kosareva S.N.
Kemerovo State Medical Academy, Ministry of Health of Russia, Kemerovo, Russia;
Kemerovo Cardiology Dispensary, Kemerovo, Russia
Barbarash O.L.
Kemerovskaia oblastnaia klinicheskaia bol'nitsa
Myocardial fibrosis: Current aspects of the problem
Journal: Therapeutic Archive. 2017;89(1): 88‑93
Views: 14638
Downloaded: 6679
To cite this article:
Karetnikova VN, Kashtalap VV, Kosareva SN, Barbarash OL. Myocardial fibrosis: Current aspects of the problem. Therapeutic Archive.
2017;89(1):88‑93. (In Russ.)
https://doi.org/10.17116/terarkh201789188-93
Fibrosis is one of the main components in the progression of most cardiovascular diseases, including coronary heart disease, by causing structural changes in the myocardium and vascular wall. The quantitative and qualitative characteristics of fibrosis of the myocardium are responsible for decreasing its elastic properties, developing diastolic dysfunction, impairing myocardial contractility, developing systolic dysfunction and cardiac arrhythmias, and worsening coronary blood flow in patients with heart failure of different etiologies. The important aspect of studying fibrosis is not only its interpretation as a model of the typical pathological process, but also its consideration as a systemic lesion of various organs and tissues. At the same time, the identification of myocardial fibrosis biomarkers that are available for their determination in circulating blood is of particular interest. Since there was evidence for the role of fibrosis in developing dysfunction of various organs and ensuring the systematicity of most diseases, especially at their development stages, the process of fibrosis came to be regarded as a promising therapeutic target. It is relevant to further investigate myocardial fibrosis, which is aimed at increasing the efficiency of its diagnosis and predicting its course and pathogenetically sound therapy.
Keywords:
Authors:
Karetnikova V.N.
Research Institute for Complex Issues of Cardiovascular Diseases, 6 Sosnovyi Boulvar, 650002, Kemerovo, Russian Federation;
Kemerovo State Medical University, 22a Voroshilova St, 650056, Kemerovo, Russian Federation
Kashtalap V.V.
Research Institute for Complex Issues of Cardiovascular Diseases, 6 Sosnovyi Boulvar, 650002, Kemerovo, Russian Federation;
Kemerovo State Medical University, 22a Voroshilova St, 650056, Kemerovo, Russian Federation
Kosareva S.N.
Kemerovo State Medical Academy, Ministry of Health of Russia, Kemerovo, Russia;
Kemerovo Cardiology Dispensary, Kemerovo, Russia
Barbarash O.L.
Kemerovskaia oblastnaia klinicheskaia bol'nitsa
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.